Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Increases By 718.6%

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 2,310,000 shares, an increase of 718.6% from the October 31st total of 282,200 shares. Based on an average trading volume of 677,400 shares, the days-to-cover ratio is currently 3.4 days. Currently, 10.5% of the shares of the stock are short sold.

IceCure Medical Stock Performance

ICCM traded up $0.05 during midday trading on Wednesday, reaching $0.84. The company had a trading volume of 488,833 shares, compared to its average volume of 581,835. The business has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.72. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.54 and a current ratio of 2.97. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.57. The stock has a market cap of $38.32 million, a PE ratio of -2.70 and a beta of 0.48.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $2.50 price objective on shares of IceCure Medical in a research report on Wednesday. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC bought a new stake in IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.